Palatin Technologies, Inc. (PTN)
12.82
-0.02
(-0.16%)
USD |
NASDAQ |
Sep 03, 15:41
Palatin Technologies Research and Development Expense (TTM) : 12.33M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2026 | 12.33M |
| December 31, 2025 | 12.57M |
| September 30, 2025 | 11.68M |
| June 30, 2025 | 14.90M |
| March 31, 2025 | 17.60M |
| December 31, 2024 | 21.00M |
| September 30, 2024 | 23.13M |
| June 30, 2024 | 22.40M |
| March 31, 2024 | 25.13M |
| December 31, 2023 | 22.80M |
| September 30, 2023 | 21.62M |
| June 30, 2023 | 22.63M |
| March 31, 2023 | 22.66M |
| December 31, 2022 | 22.81M |
| September 30, 2022 | 23.87M |
| June 30, 2022 | 21.33M |
| March 31, 2022 | 17.37M |
| December 31, 2021 | 14.90M |
| September 30, 2021 | 13.49M |
| June 30, 2021 | 12.93M |
| March 31, 2021 | 13.38M |
| December 31, 2020 | 14.51M |
| September 30, 2020 | 13.76M |
| June 30, 2020 | 13.96M |
| March 31, 2020 | 14.36M |
| Date | Value |
|---|---|
| December 31, 2019 | 14.66M |
| September 30, 2019 | 14.36M |
| June 30, 2019 | 14.86M |
| March 31, 2019 | 15.82M |
| December 31, 2018 | 18.94M |
| September 30, 2018 | 22.03M |
| June 30, 2018 | 32.57M |
| March 31, 2018 | 44.54M |
| December 31, 2017 | 46.53M |
| September 30, 2017 | 48.62M |
| June 30, 2017 | 45.68M |
| March 31, 2017 | 38.95M |
| December 31, 2016 | 40.56M |
| September 30, 2016 | 43.70M |
| June 30, 2016 | 43.07M |
| March 31, 2016 | 42.32M |
| December 31, 2015 | 39.23M |
| September 30, 2015 | 32.23M |
| June 30, 2015 | 24.56M |
| March 31, 2015 | 17.38M |
| December 31, 2014 | 11.94M |
| September 30, 2014 | 10.30M |
| June 30, 2014 | 10.83M |
| March 31, 2014 | 11.03M |
| December 31, 2013 | 11.82M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Decoy Therapeutics, Inc. | 2.230M |
| ACADIA Pharmaceuticals, Inc. | 331.01M |
| Alnylam Pharmaceuticals, Inc. | 1.509B |
| Anika Therapeutics, Inc. | 27.45M |
| Savara, Inc. | 86.84M |